Episode Details
Back to Episodes
Jones Research analyst Catherine Novack discusses Capricor's regulatory roller coaster, RNA editing, and more
Published 1 year, 2 months ago
Description
She gives a scenario analysis in the event that FDA asked Capricor for more data rather than approving the therapy by its August 31st decision date. Plus, commentary on ProQR, Korro Bio, Wave, Crinetics, Dyne, Rezolute, Larimar, and Aldeyra.